Your browser doesn't support javascript.
loading
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
Havunen, Riikka; Kalliokoski, Riikka; Siurala, Mikko; Sorsa, Suvi; Santos, João M; Cervera-Carrascon, Victor; Anttila, Marjukka; Hemminki, Akseli.
Afiliação
  • Havunen R; TILT Biotherapeutics Ltd., 00290 Helsinki, Finland.
  • Kalliokoski R; Cancer Gene Therapy Group, Translational Immunology Research Program and Department of Oncology, University of Helsinki, 00290 Helsinki, Finland.
  • Siurala M; TILT Biotherapeutics Ltd., 00290 Helsinki, Finland.
  • Sorsa S; TILT Biotherapeutics Ltd., 00290 Helsinki, Finland.
  • Santos JM; TILT Biotherapeutics Ltd., 00290 Helsinki, Finland.
  • Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program and Department of Oncology, University of Helsinki, 00290 Helsinki, Finland.
  • Anttila M; TILT Biotherapeutics Ltd., 00290 Helsinki, Finland.
  • Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program and Department of Oncology, University of Helsinki, 00290 Helsinki, Finland.
Cells ; 10(2)2021 01 27.
Article em En | MEDLINE | ID: mdl-33513935
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenoviridae / Citocinas / Vírus Oncolíticos / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cells Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenoviridae / Citocinas / Vírus Oncolíticos / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cells Ano de publicação: 2021 Tipo de documento: Article